Literature DB >> 31256680

Micropulsed diode laser cyclophotocoagulation in recurrent pediatric glaucoma.

Eman M Elhefney1, Tharwat H Mokbel1, Sherein M Hagras1, Ahmed A AlNagdy1, Adel A Ellayeh1, Tarek A Mohsen1, Walid M Gaafar1.   

Abstract

PURPOSE: To evaluate the intermediate-term efficacy and safety of micropulsed diode laser cyclophotocoagulation in recurrent pediatric glaucoma. PATIENTS AND METHODS: A prospective interventional study included children <16 years old diagnosed with recurrent glaucoma, attending Mansoura University, during the period from July 2017 to November 2017. Micropulsed diode laser sessions were performed in all the cases. The main outcome was the intraocular pressure reduction with monitoring of complications as secondary outcome. The mean follow-up period was 15.08 ± 1.1 (mean: 12-16) months.
RESULTS: A total of 36 eyes of 29 patients were included (62% males) with median age of 24 months. Primary congenital glaucoma represented 47.2% of the initial diagnoses. At the 15th month, the mean intraocular pressure dropped significantly from 37.5 ± 11.3 mmHg at baseline to 20.03 ± 2.7 mmHg (p < 0.001) with 37.15% reduction. The mean number of glaucoma medications decreased significantly from 2.6 ± 0.5 pretreatment to 1.7 ± 0.6 at the 15th month (p < 0.001). A total of 24 eyes (66.7%) required second session of treatment with mean number of 1.7 ± 0.5 sessions per eye. The cumulative probability of qualified success was 69.4%, 58.3%, 52.8%, 47.2%, and 41.7% at 1, 3, 6, 12, and 15 months after treatment. Qualified success was achieved in 61% at 15 months without statistically significant difference between the initial diagnoses (p = 0.61). None of the eyes developed any major ocular complications throughout the follow-up period.
CONCLUSION: Micropulsed diode laser was proved to be a safe approach with relative effectiveness in controlling intraocular pressure in children with recurrent glaucoma.

Entities:  

Keywords:  Cyclophotocoagulation; diode laser; micropulsed; pediatric glaucoma; recurrent

Mesh:

Year:  2019        PMID: 31256680     DOI: 10.1177/1120672119858226

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  5 in total

1.  Micropulse Transscleral Cyclophotocoagulation for Glaucoma after Penetrating Keratoplasty.

Authors:  Mihail Zemba; Otilia-Maria Dumitrescu; Alina-Cristina Stamate; Ileana Ramona Barac; Calin Petru Tataru; Daniel Constantin Branisteanu
Journal:  Diagnostics (Basel)       Date:  2022-05-05

2.  Evidence-Based Consensus Guidelines Series for MicroPulse Transscleral Laser Therapy: Dosimetry and Patient Selection.

Authors:  Tomas M Grippo; Ronald M P C de Crom; Michael Giovingo; Marc Töteberg-Harms; Brian A Francis; Brian Jerkins; Jacob W Brubaker; Nathan Radcliffe; Jella An; Robert Noecker
Journal:  Clin Ophthalmol       Date:  2022-06-07

3.  Micropulse vs. continuous wave transscleral cyclophotocoagulation in neovascular glaucoma.

Authors:  Mihail Zemba; Otilia-Maria Dumitrescu; Florin Vaida; Elena-Andreea Dimirache; Iulia Pistolea; Alina Cristina Stamate; Marian Burcea; Daniel Constantin Branisteanu; Florian Balta; Ileana Ramona Barac
Journal:  Exp Ther Med       Date:  2022-02-11       Impact factor: 2.447

4.  Ciliochoroidal effusion and its association with the outcomes of micropulse transscleral laser therapy in glaucoma patients: a pilot study.

Authors:  Sunee Chansangpetch; Natnaree Taechajongjintana; Kitiya Ratanawongphaibul; Rath Itthipanichpong; Anita Manassakorn; Visanee Tantisevi; Prin Rojanapongpun; Shan C Lin
Journal:  Sci Rep       Date:  2022-09-30       Impact factor: 4.996

5.  Topical Anesthesia Offers Sufficient Pain Control for MicroPulse Transscleral Laser Therapy for Glaucoma.

Authors:  Belgin Vasella; Marc Töteberg-Harms
Journal:  J Ophthalmol       Date:  2022-09-21       Impact factor: 1.974

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.